个人简介

王晨然，女，博士，副研究员。2017年毕业于香港科技大学，获得硕士学位。随后于2018年至2021年师从叶文才教授在暨南大学药学院攻读博士学位，2022年加入暨南大学临床医学博士后科研流动站完成博士后研究工作。2024年入职暨南大学药学院从事教学科研工作。本人主要围绕中药及天然产物抗肿瘤活性成分筛选及其分子机制研究。目前已从多种天然产物及衍生物中筛选出多个低毒高效、结构特殊与机制新颖的小分子化合物，有助于为抗肿瘤药物研发提供新型先导化合物和理论支持。主持国家自然科学基金青年项目 1 项和博士后面上项目 1 项，参与国家科技部“重大新药创制”科技重大专项、国家自然科学基金重点项目、国家自然科学基金-广东联合基金项目等多个重点项目的申请和实施工作。发表SCI论文10余篇，总影响因子累计 168.34，单篇最高他引用578次。其中以第一或共同第一作者在Nature子刊Nature Metab、国际权威期刊Drug Res Update、Signal Transduct Target Ther、Cell Death Dis等杂志发表论文。

研究方向

1.中药及天然产物抗肿瘤活性成分筛选及其分子机制研究

2.肿瘤周细胞代谢调控肿瘤耐药及转移机制研究

代表性论文：

1.Wang CR, Huang MH, Lin YN, Zhang YN, Pan JH, Jiang C, Cheng MJ, Li SR, He WZ, Li ZQ, Tu ZC, Fan J, Zeng HH, Lin JH, Wang YJ, Yao N, Liu TZ, Qi Q, Liu XN, Zhang ZM, Chen MF*, Xia LP*, Zhang DM*, Ye WC*. ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy. Nature Metabolism, 2023, 5(10): 1765-1786. (IF: 20.8)

2.Yao N, Wang CR, Liu MQ, Li YJ, Chen WM, Li ZQ, Qi Q, Lu J-J, Fan CL, Chen MF, Qi M, Li XB, Hong J, Zhang DM*, Ye WC*. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth. Signal Transduction and Targeted Therapy, 2020, 5: 214. (IF: 39.3)

3.Huang MH, Lin YN, Wang CR, Deng LJ, Chen MF, Assaraf YG, Chen ZS*, Ye WC*, Zhang DM*. New insights into antiangiogenic therapy resistance in cancer: mechanisms and therapeutic aspects. Drug Resistance Updates, 2022, 64: 100849. (IF: 24.3) 

4. Yao N, Wang CR, Hu N, Li YJ, Liu MQ, Lei YH, Chen MF, Chen LP, Chen C, Lan P, Chen WM, Chen ZS, Fu DR, Ye WC*; Zhang DM*.  Inhibition of PINK1/Parkin-dependent mitophagy sensitizes multidrug-resistant cancer cells to B5G1, a new betulinic acid analog. Cell Death & Disease, 2019, 10(3): 232. (IF: 9.0)

5.Li XB, Qi Q, Li Y, Miao Q, Yin WQ, Pan JH, Zhao Z, Chen XY, Yang F, Zhou XF, Huang MH, Wang CR, Deng LJ, Huang DD, Qi M, Fan SR, Zhang YR, Qiu SH, Deng WQ, Liu TZ, Chen MF*, Ye WC*, Zhang DM*. TCAF2 in pericytes promotes colorectal cancer liver metastasis via inhibiting cold-sensing TRPM8 channel. Advanced Science, 2023, 2302717. (IF: 15.1)

6.Wen Q, Huang MH, Xie JW, Liu RY, Miao Q, Huang JJ, Zhang JQ, lyu WY, Qi M, Wu CY, Qi Q, Zhang ZJ, Deng R, Wang CR, Chen ZS, Zhang DM*, Ye WC*, Chen MF*. lncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2. Drug Resistance Updates, 2023, 69: 100975. (IF: 24.3)

7.Ye GN, Jiao YB, Deng LJ, Cheng MJ, Wang S, Zhang JQ, Ouyang J, Li Y, He YX, Tu ZC, Wang Z, Song XJ, Wang CR, Qi Q, Zhang DM, Wang L*, Huang MH*, Ye WC*, Chen MF*. Beauvericin suppresses the proliferation and pulmonary metastasis of osteosarcoma by selectively inhibiting TGFBR2 pathway. International Journal of Biological Sciences, 2023; 19(14): 4. (IF: 9.2) 

8.He J, Hu LJ, Huang XJ, Wang CR, Zhang ZM, Wang Y, Zhang DM*, Ye WC*. Potential of coronavirus 3C-like protease inhibitors for the development of new anti SARS-CoV-2 drugs: Insights from structures of protease and inhibitors. International Journal of Antimicrobial Agents, 2020, 56(2): 106055 (IF: 15.44)

9.Liu DL, Li YJ, Yang DH, Wang CR, Xu J, Yao N, Zhang XQ, Chen*Z-S, Ye WC*, Zhang DM*. Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells. International Journal of Oncology, 2015, 5(46): 2029-2038 (IF: 5.8)

10.Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye WC*, Zhang DM*, Chen Z-S*. Autophagy and multidrug resistance in cancer. Chinese Journal of Cancer, 2017,36(1):52. (IF: 5.1)